GEN Exclusives

More »

GEN News Highlights

More »
Feb 18, 2009

Opsona Closes $23M Financing Round

Opsona Closes $23M Financing Round

Opsona to open new facility in Switzerland

  • Opsona Therapeutics completed an €18 million, or $23 million, Series B financing round. The money will allow the firm to expand its operations into Switzerland and advance its preclinical pipeline of drug candidates targeting inflammatory diseases.

    Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital, and Seroba Kernel Life Sciences participated in the funding. Under the financing agreement, Opsona added Florent Gros, managing director at Novartis, and Manus Rogan, Ph.D., managing partner at Fountain Healthcare, to the board of directors. The company says other key appointments in the corporate and clinical areas will be announced in the coming months.

    The Dublin-based company will open a new facility in Switzerland to carry out assay development and biochemical work to expand Opsona's pipeline of immunomodulators. The company's lead product is a fully humanized mAb to a TLR, which will start clinical trials in 2010, explains Opsona.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?